Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation. Comprehensive evaluation is crucial to tailor treatment plans ...

IPF severely impacts quality of life, limiting daily activities due to progressive respiratory decline. Median survival for IPF patients is approximately 3 to 5 years post-diagnosis. The financial ...

In turn, CBX7 was involved in the activation of KLF2 target genes, including genes related to endothelial-to-mesenchymal transition (endoMT), WNT9, and TEK. Here, we show that a loss of Cbx7a/CBX7 ...

No­var­tis has ter­mi­nat­ed a mid-stage tri­al of an oral treat­ment can­di­date for id­io­path­ic pul­monary fi­bro­sis, the com­pa­ny con­firmed to End­points News.

Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial. The trial ...

School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China Macrophage-myofibroblast ...